Atrion (ATRI) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a strong sell rating to a sell rating in a report issued on Thursday morning.

Shares of ATRI stock opened at $604.05 on Thursday. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of 31.94 and a beta of 0.63. Atrion has a 52 week low of $516.85 and a 52 week high of $694.00.

Get Atrion alerts:

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Wednesday, May 9th. The medical instruments supplier reported $4.56 EPS for the quarter. The business had revenue of $39.40 million for the quarter. Atrion had a net margin of 23.82% and a return on equity of 19.34%.

The business also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 15th will be paid a $1.20 dividend. This represents a $4.80 annualized dividend and a yield of 0.79%. The ex-dividend date is Thursday, June 14th.

A number of hedge funds have recently made changes to their positions in ATRI. Neuberger Berman Group LLC lifted its stake in Atrion by 18.1% in the 1st quarter. Neuberger Berman Group LLC now owns 101,923 shares of the medical instruments supplier’s stock worth $64,344,000 after purchasing an additional 15,638 shares in the last quarter. BlackRock Inc. lifted its stake in Atrion by 2.6% in the 4th quarter. BlackRock Inc. now owns 100,724 shares of the medical instruments supplier’s stock worth $63,516,000 after purchasing an additional 2,549 shares in the last quarter. BancorpSouth Bank purchased a new stake in Atrion in the 4th quarter worth $1,426,000. Millennium Management LLC lifted its stake in Atrion by 246.8% in the 1st quarter. Millennium Management LLC now owns 2,719 shares of the medical instruments supplier’s stock worth $1,717,000 after purchasing an additional 1,935 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Atrion by 2.6% in the 4th quarter. Renaissance Technologies LLC now owns 59,700 shares of the medical instruments supplier’s stock worth $37,647,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

About Atrion

Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.